NRx Pharmaceuticals, Inc. (NRXP)
NRx Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Wilmington, DE, US. The stock last traded at $3.41, up 0.19% on the session, giving a market capitalisation of $58.9M. On trailing twelve-month figures it carries a trailing P/E of -2.66, a net margin of -1070.3%. Its beta of 2.18 implies it has historically moved more than the broad market.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
NRx Pharmaceuticals, Inc. is most often compared with the following Healthcare names: